Bourin M, Poisson L, Larousse C
Neuropsychobiology. 1986;16(2-3):93-6. doi: 10.1159/000118305.
Two psychopharmacological tests which usually predict neuroleptic activity were conducted after joint administration of piracetam and three neuroleptics (haloperidol, fluphenazine and sulpiride) chosen for their different chemical classes and dopaminergic affinities. In these tests, specific doses of the neuroleptics were used to determine whether piracetam induced potentiation or antagonism of their action. Overall, piracetam increased neuroleptic action regardless of the administration timetable used, but the interaction of fluphenazine differed from that of the other two substances, because piracetam did not modify its action in a specific test of the presynaptic DA-2 dopaminergic receptors. This variation for fluphenazine may be explained by the fact that its pKa value is closer to that of piracetam, thus preventing better bioavailability of the neuroleptic, or its better affinity for DA-1 dopaminergic receptors. Nevertheless, the variation may have been due to a differing affinity for dopaminergic receptors, although this hypothesis is not completely satisfactory because it does not account for differences due to the administration timetable. It is thus suggested that action occurs on nonspecific sites and has the effect of increasing overall neuroleptic bioavailability.
在联合给予吡拉西坦与三种因其不同化学类别和多巴胺能亲和力而挑选出的抗精神病药物(氟哌啶醇、氟奋乃静和舒必利)之后,进行了两项通常可预测抗精神病活性的精神药理学测试。在这些测试中,使用特定剂量的抗精神病药物来确定吡拉西坦是否会诱导其作用的增强或拮抗。总体而言,无论采用何种给药时间表,吡拉西坦都会增强抗精神病药物的作用,但氟奋乃静的相互作用与其他两种物质不同,因为在突触前DA - 2多巴胺能受体的特定测试中,吡拉西坦并未改变其作用。氟奋乃静的这种差异可能是由于其pKa值更接近吡拉西坦,从而阻止了抗精神病药物更好的生物利用度,或者是由于其对DA - 1多巴胺能受体具有更高的亲和力。然而,这种差异可能是由于对多巴胺能受体的亲和力不同所致,尽管这一假设并不完全令人满意,因为它没有解释给药时间表所导致的差异。因此,有人提出其作用发生在非特异性位点,并且具有增加抗精神病药物总体生物利用度的效果。